CO6351719A2 - Metodos para administrar formulaciones antifúngicas tópicas para el tratamiento de infecciones fúngicas - Google Patents

Metodos para administrar formulaciones antifúngicas tópicas para el tratamiento de infecciones fúngicas

Info

Publication number
CO6351719A2
CO6351719A2 CO11017742A CO11017742A CO6351719A2 CO 6351719 A2 CO6351719 A2 CO 6351719A2 CO 11017742 A CO11017742 A CO 11017742A CO 11017742 A CO11017742 A CO 11017742A CO 6351719 A2 CO6351719 A2 CO 6351719A2
Authority
CO
Colombia
Prior art keywords
formula
group
alkyl
lower alkyl
hydrogen
Prior art date
Application number
CO11017742A
Other languages
English (en)
Inventor
Gregor Cevc
Ulrich Vierl
Original Assignee
Targeted Delivery Technologies Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Targeted Delivery Technologies Ltd filed Critical Targeted Delivery Technologies Ltd
Publication of CO6351719A2 publication Critical patent/CO6351719A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dispersion Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Un compuesto de La fórmula I, un lípido y un tensoactivo; en donde el compuesto de la fórmula I tiene la siguiente fórmula estructuralEn donde (a) R1 representa un grupo dala fórmulay R2 representa hidrógeno o alquilo inferior, o R1 y R2 juntos representan un grupo de la fórmulapor lo que en las fórmulas lIa a lIi, R7 y R8 representan independientemente, hidrógeno, halógeno, trifluorometilo, hidroxi, nitro, alquilo inferior, alcoxi inferior, o -C(=O)-R15, en donde R15 representa H, hidroxilo, alquilo inferior, alcoxi (de manera que R15 junto con el grupo carbonilo es un éster), o amino (de manera que R15 junto con el grupo carbonilo es carbamoilo);R9 representa hidrógeno, halógeno, hidroxi, alquilo inferior o alcoxi inferior,X representa oxígeno, azufre, imino, alquilimino inferior o un radical de a fórmula ----(CH2)r----,p es 1, 2 ó 3,r es 1, 2 ó 3,s es 3, 4 ó 5,t es 2, 3 ó 4, y v es 3, 4, 5 ó 6; - 2 -R3 y R5 representan, independientemente, hidrógeno o alquilo inferior, y R4 representa alquilo de C1-6 o cicloalquilo de C3-8 alquilo de (C1-6); y R6 representa un grupo de la fórmulaen donde R11 representa hidrógeno, alquilo de (C1-6), opcionalmente un alquilo sustituto con a-hdiroxi; alquenilo, cicloalquilo, cicloalquilalquilo, fenilo, fenalquilo o tienilo, R12, R13 y R14 representa, independientemente, hidrógeno o alquilo inferior, yrepresenta un radical de cicloalquilideno de C5-8 opcionalmente conteniendo una doble unión; o(b) R1 representa un grupo de la fórmula lla a llg como se define bajo (a),R2 representa hidrógeno o alquilo inferior,R3 y R4 juntos forman un grupo ----(CH2)u----, en donde u es un número entero de 1 a 8, yR5 y R6 tienen los significados dados bajo (a).
CO11017742A 2008-07-23 2011-02-15 Metodos para administrar formulaciones antifúngicas tópicas para el tratamiento de infecciones fúngicas CO6351719A2 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US8311508P 2008-07-23 2008-07-23
US10211108P 2008-10-02 2008-10-02
US15018709P 2009-02-05 2009-02-05
US16812209P 2009-04-09 2009-04-09

Publications (1)

Publication Number Publication Date
CO6351719A2 true CO6351719A2 (es) 2011-12-20

Family

ID=41358304

Family Applications (1)

Application Number Title Priority Date Filing Date
CO11017742A CO6351719A2 (es) 2008-07-23 2011-02-15 Metodos para administrar formulaciones antifúngicas tópicas para el tratamiento de infecciones fúngicas

Country Status (15)

Country Link
US (2) US20100086504A1 (es)
EP (1) EP2317993A2 (es)
JP (1) JP2011529038A (es)
KR (1) KR20110039357A (es)
CN (1) CN102159202A (es)
AU (1) AU2009275230A1 (es)
CA (1) CA2731455A1 (es)
CL (1) CL2011000135A1 (es)
CO (1) CO6351719A2 (es)
EC (1) ECSP11010818A (es)
IL (1) IL210813A0 (es)
MX (1) MX2011000932A (es)
NI (1) NI201100025A (es)
PE (1) PE20110642A1 (es)
WO (1) WO2010010470A2 (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105125529A (zh) 2007-02-05 2015-12-09 亲生物有限公司 烯丙胺药物化合物的增加的效力
JP2012516889A (ja) * 2009-02-05 2012-07-26 ターゲッティド デリバリー テクノロジーズ リミテッド 微生物因子の増殖及び生存能力を低下させる方法
FR2954163B1 (fr) * 2009-12-18 2012-03-16 Galderma Pharma Sa Utilisation d'un tensioactif cationique, avantageu-sement amphotere, pour la preparation d'une composition antifongique applicable sur l'ongle
AU2010336441B2 (en) * 2009-12-23 2015-02-05 Nuvo Research Inc. Highly permeating terbinafine formulation for treating onychomycosis
PT2672962E (pt) 2011-02-11 2015-05-25 Moberg Pharma Ab Nova composição antifúngica
WO2012126966A2 (en) * 2011-03-21 2012-09-27 Gregor Cevc Optimised preparations of highly adaptable aggregates
WO2013057208A1 (en) 2011-10-18 2013-04-25 Targeted Delivery Technologies Limited Compositions and methods for reducing the proliferation and viability of microbial agents
US8697753B1 (en) * 2013-02-07 2014-04-15 Polichem Sa Method of treating onychomycosis
WO2015138926A1 (en) 2014-03-14 2015-09-17 Gojo Industries, Inc. Hand sanitizers with improved aesthetics and skin-conditioning to encourage compliance with hand hygiene guidelines
AT516544B1 (de) 2014-12-02 2017-05-15 Universität Innsbruck Stoffgemisch und Zubereitung
CN105193726B (zh) * 2015-11-08 2018-01-26 长沙佰顺生物科技有限公司 一种治疗灰指甲的药物组合物
KR101952715B1 (ko) * 2017-09-27 2019-02-27 경희대학교 산학협력단 천연 화합물을 포함하는 칸디다증 개선용 항진균 조성물
RU2698454C1 (ru) * 2018-11-12 2019-08-27 Федеральное государственное бюджетное образовательное учреждение высшего образования "Кубанский государственный медицинский университет" Министерства здравоохранения Российской Федерации (ФГБОУ ВО КубГМУ Минздрава России) Способ лечения онихомикозов стоп
KR102072946B1 (ko) 2019-08-06 2020-02-03 주식회사 씨엔엘바이오텍 조갑진균증 예방 또는 치료용 조성물
CA3157201A1 (en) * 2019-10-08 2021-04-15 Hallux Inc. Onychomycosis treatment compositions and methods
AT524378A1 (de) 2020-11-06 2022-05-15 Univ Innsbruck Zubereitung
KR20230116911A (ko) * 2020-12-08 2023-08-04 모베르그 파르마 아베 알릴아민 항진균 조성물을 사용한 조갑진균증의 치료 요법

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE10272T1 (de) * 1979-08-22 1984-11-15 Sandoz Ag Propenylamine, verfahren zu ihrer herstellung, sie enthaltende pharmazeutische zusammensetzungen und ihre verwendung als arzneimittel.
US6005001A (en) * 1991-05-20 1999-12-21 Novartis Ag (Formerly Sandoz Ag) Pharmaceutical composition
GB9111611D0 (en) * 1991-05-30 1991-07-24 Sandoz Ltd Liposomes
JP2002505307A (ja) * 1998-03-05 2002-02-19 ファレス ファーマシューティカル リサーチ エヌブイ 薬学的組成物およびその使用
US6383471B1 (en) * 1999-04-06 2002-05-07 Lipocine, Inc. Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents
GB0108082D0 (en) * 2001-03-30 2001-05-23 Novartis Consumer Health Sa Topical composition
US6846837B2 (en) * 2002-06-21 2005-01-25 Howard I. Maibach Topical administration of basic antifungal compositions to treat fungal infections of the nails
US20040105881A1 (en) * 2002-10-11 2004-06-03 Gregor Cevc Aggregates with increased deformability, comprising at least three amphipats, for improved transport through semi-permeable barriers and for the non-invasive drug application in vivo, especially through the skin
EP1734925A2 (en) * 2004-03-18 2006-12-27 Panacea Biotec Ltd. Novel compositions for topical delivery
US20060078580A1 (en) * 2004-10-08 2006-04-13 Mediquest Therapeutics, Inc. Organo-gel formulations for therapeutic applications
WO2006103638A2 (en) * 2005-03-31 2006-10-05 Ranbaxy Laboratories Limited Topical pharmaceutical compositions of terbinafine and processes for their preparation
US20070077283A1 (en) * 2005-09-30 2007-04-05 Nastech Pharmaceutical Company Inc. Method of enhancing transmucosal delivery of therapeutic compounds
JP5467722B2 (ja) * 2007-01-16 2014-04-09 ロート製薬株式会社 皮膚外用乳化製剤
CN105125529A (zh) * 2007-02-05 2015-12-09 亲生物有限公司 烯丙胺药物化合物的增加的效力

Also Published As

Publication number Publication date
WO2010010470A3 (en) 2010-03-18
IL210813A0 (en) 2011-04-28
AU2009275230A1 (en) 2010-01-28
US20100104633A1 (en) 2010-04-29
EP2317993A2 (en) 2011-05-11
WO2010010470A2 (en) 2010-01-28
NI201100025A (es) 2011-11-02
MX2011000932A (es) 2011-05-19
KR20110039357A (ko) 2011-04-15
US20100086504A1 (en) 2010-04-08
ECSP11010818A (es) 2011-05-31
CL2011000135A1 (es) 2011-09-23
JP2011529038A (ja) 2011-12-01
US7820720B2 (en) 2010-10-26
CN102159202A (zh) 2011-08-17
CA2731455A1 (en) 2010-01-28
PE20110642A1 (es) 2011-08-31

Similar Documents

Publication Publication Date Title
CO6351719A2 (es) Metodos para administrar formulaciones antifúngicas tópicas para el tratamiento de infecciones fúngicas
EA201390934A1 (ru) Композиции и способы модулирования fxr
AR077701A1 (es) Compuestos antiproliferativos, conjugados de los mismos, procedimientos para estos, y usos de los mismos
EA201500653A1 (ru) Композиции, содержащие триазольное соединение
EA201001554A1 (ru) Ингибиторы модуляторов воспаления: производные олеанолевой кислоты, гомологированные с-17
EA201001555A1 (ru) Антиоксидативные модуляторы воспаления: производные олеанолевой кислоты с аминовыми и другими модификациями на с-17
AR047817A1 (es) Derivados de aril- y heteroarilpiperidincarboxilatos, su preparacion y su aplicacion en terapeutica
AR049291A1 (es) Derivados de pirazol, composiciones que contienen dichos compuestos y procedimientos de uso
EA201001682A1 (ru) Производные фенил- и бензодиоксинилзамещенных индазолов
AR076360A1 (es) Derivados de 3,3'-espiroindolinona y su uso en el tratamiento del cancer
PE20150400A1 (es) Benzamidas n-sustituidas y su uso en el tratamiento del dolor
AR055297A1 (es) Ligandos moduladores de los receptores rars, utilizacion en medicina humana asi como en cosmetica
EA201071040A1 (ru) Новые производные 1-бензил-3-гидроксиметилиндазола и их применение при лечении заболеваний, обусловленных экспрессией mcp-1, cx3cr1 и p40
EA201290128A1 (ru) Новые макроциклические ингибиторы репликации вируса гепатита с
AR070828A1 (es) Derivados de azetidina y ciclobutano como inhibidores de jak
MD4425C1 (ro) Alcoxipirazoli în calitate de activatori ai guanilat-ciclazei solubile
EA201490287A1 (ru) Новые замещенные производные индола в качестве модуляторов гамма-секретазы
EA201491598A1 (ru) Композиция для борьбы с вредителями, включающая новое производное иминопиридина
AR054790A1 (es) Metodos para el tratamiento de disfuncion sexual
PE20120374A1 (es) Fenilureas y fenilamidas como ligandos del receptor de vanilloides
EA201491079A1 (ru) Арил дигидропиридиноновые и пиперидиноновые ингибиторы mgat2
CO6351789A2 (es) Derivados de carbamatos de alquiltiazoles, su preparacion y su aplicacion en terapeutica
ATE538100T1 (de) Aminotetrahydroindazoloessigsäuren
AR086773A1 (es) Un derivado de cinamida sustituida, el metodo para su preparacion y el uso del mismo
AR067975A1 (es) Derivados de la n-bencil, n-arilcarbonilpiperazina

Legal Events

Date Code Title Description
FC Application refused